Eli Lilly said Tuesday that it’s changed the outcome goals for a late-stage patient study of its closely watched experimental drug for Alzheimer’s disease, solanezumab.
from Dementia Big http://ift.tt/1QVYla0 via alcoholic dementia
http://ift.tt/1SSq1xM
No comments:
Post a Comment